|
2020 Journal Article Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE)Ahern, Elizabeth, Allen, Michael J., Schmidt, Andrew, Lwin, Zarnie and Hughes, Brett G. M. (2020). Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE). Asia-Pacific Journal of Clinical Oncology, 17 (2) ajco.13350, e109-e116. doi: 10.1111/ajco.13350 |
|
2020 Journal Article Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412Machiels, Jean-Pascal, Tao, Yungan, Burtness, Barbara, Tahara, Makoto, Licitra, Lisa, Rischin, Danny, Waldron, John, Simon, Christian, Gregoire, Vincent, Harrington, Kevin, Alves, Gustavo Vasconcelos, Figueiredo Lima, Iane Pinto, Pointreau, Yoann, M Hughes, Brett G., Aksoy, Sercan, Hetnal, Marcin, Ge, Joy Y., Brown, Holly, Cheng, Jonathan, Bidadi, Behzad and Siu, Lillian L. (2020). Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Future oncology (London, England), 16 (18), 1235-1243. doi: 10.2217/fon-2020-0184 |
|
2020 Journal Article Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingRischin, Danny, Migden, Michael R., Lim, Annette M., Schmults, Chrysalyne D., Khushalani, Nikhil I., Hughes, Brett G. M., Schadendorf, Dirk, Dunn, Lara A., Hernandez-Aya, Leonel, Chang, Anne Lynn S., Modi, Badri, Hauschild, Axel and Ulrich, Claas (2020). Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. Journal for immunotherapy of cancer, 8 (1) e000775. doi: 10.1136/jitc-2020-000775 |
|
2020 Journal Article Weighted activity unit effect: evaluating the cost of diagnosis-related group codingTan, Joanne Y.-A., Senko, Clare, Hughes, Brett, Lwin, Zarnie, Bennett, Richard, Power, John and Thomson, Leah (2020). Weighted activity unit effect: evaluating the cost of diagnosis-related group coding. Internal Medicine Journal, 50 (4), 440-444. doi: 10.1111/imj.14373 |
|
2020 Journal Article A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancerAlexander, Marliese, Pavlakis, Nick, John, Thomas, O'Connell, Rachel, Kao, Steven, Hughes, Brett G.M., Lee, Adrian, Hayes, Sarah A., Howell, Viive M., Clarke, Stephen J., Millward, Michael, Burbury, Kate, Solomon, Benjamin and Itchins, Malinda (2020). A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. Lung Cancer, 142, 34-40. doi: 10.1016/j.lungcan.2020.01.017 |
|
2020 Journal Article An occult HPV-driven oropharyngeal squamous cell carcinoma discovered through a saliva testTang, Kai Dun, Vasani, Sarju, Taheri, Touraj, Walsh, Laurence J., Hughes, Brett G. M., Kenny, Lizbeth and Punyadeera, Chamindie (2020). An occult HPV-driven oropharyngeal squamous cell carcinoma discovered through a saliva test. Frontiers in Oncology, 10 408, 408. doi: 10.3389/fonc.2020.00408 |
|
2020 Journal Article Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancerRatnayake, Gishan, Shanker, Mihir, Roberts, Kate, Mason, Robert, Hughes, Brett G. M., Lwin, Zarnie, Jain, Vikram, O'Byrne, Kenneth, Lehman, Margot and Chua, Benjamin (2020). Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 16 (1), 56-62. doi: 10.1111/ajco.13242 |
|
2020 Journal Article Outcomes of incidental pulmonary nodules in head-and-neck squamous cell cancer patients treated with curative intentTani, Daniel, Ladwa, Rahul, Xu, Wen, Lwin, Zarnie, Steinke, Karin and Hughes, Brett G. M. (2020). Outcomes of incidental pulmonary nodules in head-and-neck squamous cell cancer patients treated with curative intent. Journal of Head and Neck Physicians and Surgeons, 8 (1), 17-22. doi: 10.4103/jhnps.jhnps_39_19 |
|
2020 Journal Article Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancerFong, Lawrence, Hotson, Andrew, Powderly, John D., Sznol, Mario, Heist, Rebecca S., Choueiri, Toni K., George, Saby, Hughes, Brett G. M., Hellmann, Matthew D., Shepard, Dale R., Rini, Brian I., Kummar, Shivaani, Weise, Amy M., Riese, Matthew J., Markman, Ben, Emens, Leisha A., Mahadevan, Daruka, Luke, Jason J., Laport, Ginna, Brody, Joshua D., Hernandez-Aya, Leonel, Bonomi, Philip, Goldman, Jonathan W., Berim, Lyudmyla, Renouf, Daniel J., Goodwin, Rachel A., Munneke, Brian, Ho, Po Y., Hsieh, Jessica ... Miller, Richard A. (2020). Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer. Cancer Discovery, 10 (1), 40-53. doi: 10.1158/2159-8290.CD-19-0980 |
|
2019 Journal Article Bilateral acute anterior uveitis: a rare ocular side effect of erlotinibChan, Sarah, Ahern, Elizabeth, Chaudhry, Sarah and Hughes, Brett (2019). Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib. BMJ case reports, 12 (12) e232868, e232868. doi: 10.1136/bcr-2019-232868 |
|
2019 Journal Article EGFR mutations in lung cancer: not all equal in the eyes of the immune system?Fong, Kwun M., Hughes, Brett G. M., Lwin, Zarnie and Yang, Ian A. (2019). EGFR mutations in lung cancer: not all equal in the eyes of the immune system?. Annals of Translational Medicine, 7 (S8) S326, S326-S326. doi: 10.21037/atm.2019.09.132 |
|
2019 Conference Publication Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC)Rischin, D., Khushalani, N. I., Schmults, C. D., Guminski, A., Chang, A. L. S., Lewis, K. D., Lim, A. M., Hernandez-Aya, L., Hughes, B. G. M., Schadendorf, D., Hauschild, A., Stankevich, E., Booth, J., Li, S., Chen, Z., Desai, J., Lowy, I., Fury, M. G. and Migden, M. R. (2019). Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC). Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva Switzerland, Dec 11-14, 2019. OXFORD: OXFORD UNIV PRESS. |
|
2019 Journal Article Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)Ahern, Elizabeth, Cubitt, Annette, Ballard, Emma, Teng, Michele W. L., Dougall, William C., Smyth, Mark J., Godbolt, David, Naidoo, Rishendran, Goldrick, Amanda and Hughes, Brett G. M. (2019). Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). Trials, 20 (1) 753, 753. doi: 10.1186/s13063-019-3951-x |
|
2019 Journal Article An update: circulating tumor cells in head and neck cancerKulasinghe, Arutha, Hughes, Brett G. M., Kenny, Liz and Punyadeera, Chamindie (2019). An update: circulating tumor cells in head and neck cancer. Expert Review of Molecular Diagnostics, 19 (12), 1109-1115. doi: 10.1080/14737159.2020.1688145 |
|
2019 Journal Article Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBurtness, Barbara, Harrington, Kevin J, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G. M., Mesía, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Hong, Ruey-Long, González Mendoza, René, Roy, Ananya, Zhang, Yayan, Gumuscu, Burak, Cheng, Jonathan D, Jin, Fan, Rischin, Danny, Lerzo, Guillermo, Tatangelo, Marcelo, Varela, Mirta, Zarba, Juan Jose, Boyer, Michael ... Yorio, Jeffrey (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet, 394 (10212), 1915-1928. doi: 10.1016/S0140-6736(19)32591-7 |
|
2019 Conference Publication Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 studyGrob, J. J., Gonzalez Mendoza, R., Basset-Seguin, N., Vornicova, O., Schachter, J., Joshi, A., Meyer, N., Grange, F., Piulats, J. M., Bauman, J., Zhang, P., Gumuscu, B., Swaby, R. F. and Hughes, B. G. M. (2019). Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona Spain, Sep 27-Oct 01, 2019. OXFORD: OXFORD UNIV PRESS. |
|
2019 Conference Publication Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)Rischin, D., Lim, A. M., Schmults, C. D., Khushalani, N. I., Hughes, B. G., Schadendorf, D., Dunn, L. A., Chang, A. L. S., Hauschild, A., Ulrich, C., Eigentler, T., Migden, M. R., Pavlick, A. C., Geiger, J., Stankevich, E., Li, S., Lowy, I., Fury, M. G. and Guminski, A. (2019). Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC). 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 1 October 2019. Oxford, United Kingdom: Oxford University Press. |
|
2019 Journal Article Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNCMoroney, Laura B., Ward, Elizabeth C., Helios, Jennifer, Crombie, Jane, Burns, Clare L., Blake, Claire, Comans, Tracy, Chua, Benjamin, Kenny, Lizbeth and Hughes, Brett G. M. (2019). Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC. Supportive Care in Cancer, 28 (4), 1867-1876. doi: 10.1007/s00520-019-04992-x |
|
2019 Journal Article Traveling with cancer: a guide for oncologists in the modern worldHeng, Sharon, Hughes, Brett, Hibbert, Michael, Khasraw, Mustafa and Lwin, Zarnie (2019). Traveling with cancer: a guide for oncologists in the modern world. Journal of Global Oncology, 5 (5) Y, 1-10. doi: 10.1200/JGO.19.00029 |
|
2019 Conference Publication KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinomaGrob, Jean-Jacques, Gonzalez Mendoza, Rene, Basset-Seguin, Nicole, Schachter, Jacob, Vornicova, Olga, Bauman, Jessica, Grange, Florent, Meyer, Nicolas, Piulats, Josep, Zhang, Pingye (Eric), Gumuscu, Burak, Swaby, Ramona and Hughes, Brett G. M. (2019). KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma. AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology, Atlanta Ga, Mar 29-Apr 03, 2019. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. doi: 10.1158/1538-7445.AM2019-CT170 |
